| Entry |
|
|---|
| Name |
Cytarabine ocfosfate hydrate (JAN);
Cytarabine ocfosphate hydrate;
Fosteabine sodium monohydrate;
Starasid (TN) |
|---|
| Formula |
C27H49N3O8P. Na. H2O
|
|---|
| Exact mass |
615.3261
|
|---|
| Mol weight |
615.67
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
|
|---|
| Remark |
| Therapeutic category: | 4224 |
| Product (DG00686): | D00168<JP/US> D03046<JP> |
|
|---|
| Efficacy |
Antineoplastic, Antimetabolite |
|---|
| Comment |
Active form of prodrug: Cytarabine [DR: D00168]
|
|---|
| Target |
DNA polymerase |
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BC Pyrimidine analogues
L01BC01 Cytarabine
D03046 Cytarabine ocfosfate hydrate (JAN) <JP>
USP drug classification [BR:br08302]
Antineoplastics
Antimetabolites
Cytarabine
D03046 Cytarabine ocfosfate hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4224 Cytosines
D03046 Cytarabine ocfosfate hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00686 Cytarabine
D03046 Cytarabine ocfosfate hydrate
Drug classes [BR:br08332]
Antineoplastic
DG02018 Antimetabolite
D03046 Cytarabine ocfosfate hydrate
Prodrugs [br08324.html]
D03046
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00686 Cytarabine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 41
1 C1y C 35.8364 -16.8675
2 N4y N 37.1806 -16.3426
3 O2x O 34.7127 -16.0505
4 C1y C 35.4078 -18.1826
5 C1y C 33.5886 -16.8675
6 C1y C 34.0174 -18.1826
7 O1a O 36.2188 -19.3066
8 C8x C 37.1747 -14.9563
9 C8y C 38.3840 -17.0306
10 N5x N 39.5817 -16.3325
11 C8y C 39.5759 -14.9463
12 C8x C 38.3723 -14.2582
13 O5x O 38.3894 -18.3954
14 N1a N 40.7996 -14.2332
15 C1b C 32.3873 -16.1739
16 O2b O 31.1859 -16.8675
17 O1a O 33.2246 -19.2756
18 P1b P 29.9900 -16.1769
19 O2b O 28.7773 -16.8773
20 C1b C 27.2158 -16.1767
21 O1c O 30.9709 -15.1959 #-
22 O1c O 29.0092 -15.1959
23 C1b C 26.0032 -16.8779
24 C1b C 24.7877 -16.1775
25 C1b C 23.5763 -16.8790
26 C1b C 22.3796 -16.1704
27 C1b C 21.1670 -16.8705
28 C1b C 19.9544 -16.1704
29 C1b C 18.7419 -16.8705
30 C1b C 17.5293 -16.1704
31 C1b C 16.3167 -16.8705
32 C1b C 15.1042 -16.1704
33 C1b C 13.8916 -16.8705
34 C1b C 12.6790 -16.1704
35 C1b C 11.4664 -16.8705
36 C1b C 10.2538 -16.1704
37 C1b C 9.0413 -16.8705
38 C1b C 7.8287 -16.1704
39 C1a C 6.6161 -16.8705
40 Z Na 32.5245 -14.7624 #+
41 O0 O 41.6843 -17.6750
BOND 40
1 1 2 1 #Up
2 1 3 1
3 1 4 1
4 3 5 1
5 4 6 1
6 4 7 1 #Up
7 5 6 1
8 2 8 1
9 2 9 1
10 9 10 1
11 10 11 2
12 11 12 1
13 8 12 2
14 9 13 2
15 11 14 1
16 5 15 1 #Up
17 15 16 1
18 6 17 1 #Down
19 16 18 1
20 18 19 1
21 18 21 1
22 18 22 2
23 24 25 1
24 19 20 1
25 20 23 1
26 23 24 1
27 25 26 1
28 26 27 1
29 27 28 1
30 28 29 1
31 29 30 1
32 30 31 1
33 31 32 1
34 32 33 1
35 33 34 1
36 34 35 1
37 35 36 1
38 36 37 1
39 37 38 1
40 38 39 1
|
|---|
